scholarly journals Immune Response during Adverse Events after 17D‐Derived Yellow Fever Vaccination in Europe

2008 ◽  
Vol 197 (11) ◽  
pp. 1577-1584 ◽  
Author(s):  
Hi‐Gung Bae ◽  
Cristina Domingo ◽  
Antonio Tenorio ◽  
Fernando de Ory ◽  
José Muñoz ◽  
...  
2013 ◽  
Vol 95 (9) ◽  
pp. e59-e61 ◽  
Author(s):  
Mark K. Slifka ◽  
Erika Hammarlund ◽  
Matthew W. Lewis ◽  
Elizabeth A. Poore ◽  
Jon M. Hanifin ◽  
...  

Author(s):  
Mariângela Ottoboni Brunaldi ◽  
René Julias Costa Silva ◽  
Alexandre Todorovic Fabro ◽  
Daniel Cardoso de Almeida e Araujo ◽  
Anibal Basile-Filho ◽  
...  

Yellow fever is a viral hemorrhagic disease, and vaccination is the most effective way to minimize the impact of the disease. Serious adverse events after yellow fever vaccination are rare. We report the case of a young woman with an unusual presentation of yellow fever 17DD vaccine-associated acute viscerotropic disease, with severe hepatic impairment following a long incubation period. She died more than a month after yellow fever vaccination.


2013 ◽  
Vol 9 (2) ◽  
pp. 277-282 ◽  
Author(s):  
Karina Takesaki Miyaji ◽  
André Machado Luiz ◽  
Amanda Nazareth Lara ◽  
Tania do Socorro Souza Chaves ◽  
Roberta de Oliveira Piorelli ◽  
...  

Author(s):  
Amanda Nazareth Lara ◽  
Karina Takesaki Miyaji ◽  
Karim Yaqub Ibrahim ◽  
Marta Heloisa Lopes ◽  
Ana Marli Christovam Sartori

1992 ◽  
Vol 34 (5) ◽  
pp. 447-450 ◽  
Author(s):  
Rita M. Ribeiro Nogueira ◽  
Hermann G. Schatzmayr ◽  
Marize P. Miagostovich ◽  
Silvia M. B. Cavalcanti ◽  
Ricardo de Carvalho

An evaluation of the IgM antibody immune response against yellow fever using strain 17D was carried out by MAC-ELISA and PRNT. The results showed an agreement of 97% between both tests and the authors conclude that MAC-ELISA can be used as a specific and sensitive asssay to replace the PRNT for detecting yellow fever antibodies in human sera, after vaccination programs.


Vaccines ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 249 ◽  
Author(s):  
Cristina Domingo ◽  
Judith Lamerz ◽  
Daniel Cadar ◽  
Marija Stojkovic ◽  
Philip Eisermann ◽  
...  

Background: The yellow fever (YF) vaccination is recommended by the WHO for people traveling or living in endemic areas at risk for yellow fever infections in Africa and South America. Although the live attenuated yellow fever vaccine is a safe and efficient vaccine, rare serious adverse events after vaccination have been reported. Case presentation: We present the case of a 74-year-old male with multiorgan failure after yellow fever vaccination for a trip to Brazil. The patient required admission to the intensive care unit with a prolonged stay due to severe organ dysfunction. Five days after the YF vaccination, the patient experienced nausea, vomiting, diarrhea, and general illness. Three days later he sought medical attention and was transferred to the University Hospital Heidelberg with beginning multiorgan failure and severe septic shock, including hypotonia, tachypnea, thrombopenia, and acute renal failure the same day. Within one week after vaccination, antibodies against YF virus were already detectable and progressively increased over the next two weeks. Viral RNA was detected in serum on the day of admission, with a viral load of 1.0 × 105 copies/mL. The YF virus (YFV) RNA was also present in tracheal secretions for several weeks and could be detected in urine samples up to 20 weeks after vaccination, with a peak viral load of 1.3 × 106 copies/mL. After 20 weeks in the ICU with nine weeks of mechanical ventilation, the patient was transferred to another hospital for further recovery. Conclusions: The risk for severe adverse events due to the YF vaccination should be balanced against the risk of acquiring a severe YF infection, especially in elderly travelers.


Sign in / Sign up

Export Citation Format

Share Document